Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker

    公开(公告)号:US11543418B2

    公开(公告)日:2023-01-03

    申请号:US16630045

    申请日:2017-07-13

    IPC分类号: G01N33/68 C07K16/18

    摘要: This invention provides a method for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease using a protein and a peptide of the protein different in the presence level in subjects having a normal cognitive function and patients suffering from cognitive disfunction diseases and a biomarker for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease containing the protein and the peptide. This invention is a biomarker for diagnosing cognitive disfunction diseases containing a prothrombin precursor protein of SEQ ID NO: 1 or a peptide THRB containing the amino acid sequence represented by SEQ ID NO: 2 which is a peptide of the protein, a diagnosis method for cognitive disfunction diseases using the biomarker, an antigen peptide represented by SEQ ID NO: 3 for creating a THRB peptide specific antibody to be used in the diagnosis method, and a cognitive disfunction disease diagnosis kit containing the THRB peptide specific antibody.

    Disease detection method
    2.
    发明授权

    公开(公告)号:US11592452B2

    公开(公告)日:2023-02-28

    申请号:US16630686

    申请日:2018-07-13

    申请人: MCBI INC.

    摘要: The present invention is a method for detecting a specific disease based on the result of a measurement in which the amount of a peptide serving as a biomarker contained in a biological sample is determined by using an LC-MS. A pretreatment process performed before the measurement using the LC-MS includes the steps of preparing a mixed sample solution by adding a stable isotope reagent and a trifluoroacetic acid to the biological sample, where the stable isotope reagent is prepared beforehand by labeling the peptide with a stable isotope; boiling the mixed sample solution; injecting the mixed sample solution after boiled into a solid-phase extraction column to make the peptide be retained in the solid-phase extraction column; and passing a water-soluble organic solvent through the solid-phase extraction column to elute the peptide retained in the solid-phase extraction column and collect the eluate.

    Biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease by using such biomarkers

    公开(公告)号:US10145853B2

    公开(公告)日:2018-12-04

    申请号:US14679332

    申请日:2015-04-06

    申请人: MCBI, Inc.

    IPC分类号: G01N33/68 C07K14/81

    摘要: The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kDa protein fragment consisting of amino acid sequence expressed by Sequence No. 2 and its partial peptide consisting of amino acid sequence expressed by Sequence No. 3 (including its glycated form) of inter-alpha-trypsin inhibitor heavy chain H4 precursor consisting of amino acid sequence expressed by Sequence No. 1 could be used as biomarkers to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

    Biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers

    公开(公告)号:US11307208B2

    公开(公告)日:2022-04-19

    申请号:US16791984

    申请日:2020-02-14

    申请人: MCBI INC.

    摘要: The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.

    Biomarker for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers
    6.
    发明授权
    Biomarker for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers 有权
    包括认知障碍在内的精神疾病的生物标志物和用于检测精神疾病的方法,包括使用生物标志物的认知障碍

    公开(公告)号:US08748574B2

    公开(公告)日:2014-06-10

    申请号:US13321442

    申请日:2010-05-17

    摘要: Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21.

    摘要翻译: 提供了通过使用存在或不存在不同的蛋白质或其部分肽来检测包括轻度认知障碍和阿尔茨海默病的认知障碍的方法。 还提供了新的生物标志物用于认知障碍和非精神疾病,以及使用这种生物标志物检测认知障碍的方法。 具体地,提供了一种用于诊断的生物标志物,其包含由至少一种选自SEQ ID NO:1表示的氨基酸序列组成的蛋白质组中的至少一种蛋白质或肽产生的不少于5个氨基酸残基的蛋白质片段或肽 ,3,6,8,10,13,15,18或20,并且选自由SEQ ID NO:2,4,5,7,9,9或10所表示的氨基酸序列组成的这些蛋白质中的部分肽组, 11,12,14,16,17,19或21。

    BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASES, AND METHOD FOR DETECTION OF COGNITIVE DYSFUNCTION DISEASES USING THE BIOMARKER

    公开(公告)号:US20130337479A1

    公开(公告)日:2013-12-19

    申请号:US13995682

    申请日:2011-12-21

    IPC分类号: G01N33/68

    摘要: The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.

    BIOMARKER FOR MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS, AND METHOD USING SAID BIOMARKER TO DETECT MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS
    8.
    发明申请
    BIOMARKER FOR MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS, AND METHOD USING SAID BIOMARKER TO DETECT MENTAL DISORDERS INCLUDING COGNITIVE DISORDERS 有权
    用于包括认知障碍的精神疾病的生物标记,以及使用生物识别器检测包括认知障碍的精神疾病的方法

    公开(公告)号:US20120149034A1

    公开(公告)日:2012-06-14

    申请号:US13321442

    申请日:2010-05-17

    摘要: Methods are provided that detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence. Novel biomarkers are also provided for cognitive impairment and non-psychiatric disease, as well as methods for detecting cognitive impairment using such biomarkers. Specifically, a biomarker for diagnosis is provided that comprises a protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of an amino acid sequence expressed by SEQ ID NO: 1, 3, 6, 8, 10, 13, 15, 18, or 20 and selected from the group of partial peptide in these proteins consisting of an amino acid sequence expressed by SEQ ID NO: 2, 4, 5, 7, 9, 11, 12, 14, 16, 17, 19, or 21.

    摘要翻译: 提供了通过使用存在或不存在不同的蛋白质或其部分肽来检测包括轻度认知障碍和阿尔茨海默病的认知障碍的方法。 还提供了新的生物标志物用于认知障碍和非精神疾病,以及使用这种生物标志物检测认知障碍的方法。 具体地,提供了一种用于诊断的生物标志物,其包含由至少一种选自SEQ ID NO:1表示的氨基酸序列组成的蛋白质组中的至少一种蛋白质或肽产生的不少于5个氨基酸残基的蛋白质片段或肽 ,3,6,8,10,13,15,18或20,并且选自由SEQ ID NO:2,4,5,7,9,9或10所表示的氨基酸序列组成的这些蛋白质中的部分肽组, 11,12,14,16,17,19或21。